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Background: Rubinstein-Taybi syndrome (RSTS) is an extremely rare autosomal dominant genetic disease, with an
estimated prevalence of one case per 125,000 live births. RSTS is characterized by typical facial features,
microcephaly, broad thumbs and first toes, intellectual disability, and postnatal growth retardation. However, no
standard diagnostic criteria are available for RSTS. In this review, we summarized the clinical features and genetic
basis of RSTS and highlighted areas for future studies on an appropriate diagnostic protocol and follow-up care for
RSTS.
Discussion: RSTS is primarily characterized by delayed growth in height and weight, microcephaly, dysmorphic
facial features, and broad thumbs and big toe. Over 90% RSTS individuals with disabilities survive to adulthood, but
healthcare for these patients is particularly complex, time-consuming, and costly. In addition, no standard diagnostic
criteria and follow-up care guidelines are available for RSTS. It has been shown that mutations in the genes encoding
the cyclic-AMP-regulated enhancer binding protein (CREBBP) and the E1A-binding protein p300 (EP300) contributed to
the development of RSTS. Therefore, genetic tests are useful for the diagnosis of RSTS, although most RSTS cases are
currently diagnosed based on clinical features.
Summary: The clinical features of RSTS have been extensively studied, which significantly contributes to the diagnosis
of this extremely rare syndrome. However, the pathogenesis and genotype-phenotype associations of RSTS are largely
unknown. Therefore, multicenter studies and international cooperation are highlighted for better understanding of this
disease, establishing standard diagnostic criteria, and providing professional management and follow-up care of RSTS.
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Plurimalformative syndromes, which are named according
to their low prevalence and incidence in the population,
consist of a large group of rare diseases. Rubinstein-Taybi
syndrome (RSTS, OMIM #180849, #613684) is an ex-
tremely rare disease and was first described in 1963 [1].
The incidence of RSTS is 1 in 100,000 to 125,000 live
births. Currently, no precise diagnostic criteria are avail-
able, although RSTS is primarily characterized by poor
postnatal height-weight growth, intellectual disability,
microcephaly, dysmorphic facial features, broad thumbs,
and big first toes. While a number of major malformations* Correspondence: susanna.esposito@unimi.it
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unless otherwise stated.and clinical complications are associated with RSTS, these
signs and symptoms cannot be considered pathogno-
monic to RSTS. Until the 90s, diagnosis has remained ex-
clusively clinical and radiological (x-ray of hands and feet).
The genetic bases were first identified in 1991, demon-
strating a de novo reciprocal translocation with break-
points in chromosomal region 16p13.3 in some patients
[2-4]. Subsequently, affected subjects were analyzed using
Fluorescent In Situ Hybridization (FISH). In six cases, the
hybridization signal was present on only one allele on
16p13.3, confirming that the absence of this region lead to
RSTS [5,6]. Additional research has led to the discovery of
mutations in the gene encoding cyclic-AMP-regulated en-
hancer binding protein (CREBBP) in 16p13.3 in RSTS pa-
tients [7]. Mutations of CREBBP gene were reported inThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and its homolog, E1A binding protein p300 (EP300) on
chromosome 22, are involved in a number of basic cellular
activities, such as DNA repair, growth, differentiation,
apoptosis of cells, and tumor suppression by serving as
transcriptional co-activators in different signaling path-
ways [10]. As CREBBP and EP300 interact closely, studies
have been conducted to investigate whether mutations in
EP300 were associated with RSTS. The results of EP300
sequencing in a group of six subjects revealed three
mutations [11]. Subsequently, the incidence of EP300
mutations was estimated as about 5-8% [12-16]. Generally,
55-70% clinically diagnosed RSTS cases were confirmed
through genetic testing [17]. In this review, we discussed
the clinical features and genetic studies of RSTS and we try
to outline future directions for an appropriate clinical diag-
nosis and follow-up of this condition.
Discussion
Typical features
RSTS is characterized by slow development of height
and weight, microcephaly, dysmorphic facial features,
broad thumbs, and big toes [18]. The prenatal develop-
ment is normal, with average or near-normal growth pa-
rameters at birth. The growth charts typically approach
the lower limits of normality in the first postnatal period,
primarily reflecting hypo-feeding exacerbated by gastro-
esophageal reflux. Subsequently, the tendency of over-
weight or obesity (earlier in males than females) can be
observed during adolescence. Specific and recently reviewed
growth charts are essential for appropriate assessment of the
growth of affected individuals [18]. Facial features are pri-
marily characterized by low frontal hairline, arched/thick
eyebrows, downslanting of palpebral fissures, a protruding
beaked nose with columella below alae nasi, dysplastic and
low-set ears, an arched palate, mild micrognathia, dental
anomalies (altered conformation, malocclusion, and over-
crowding of teeth), and atypical smile (“grimacing”) with
nearly completely closed eyes (Figure 1). The feet and hands
typically present an enlarged first finger and clinodactyly of
the fifth finger (Figure 2), whereas polydactyly with bifid
thumbs and first toes is rarely observed. Other skeletal
anomalies include abducted thumbs, vertebral anomalies,
ligamentous laxity, severe and prolonged aseptic inflamma-
tion of the femur head, anomalies similar with Perthes dis-
ease (3%), and occasionally slipped capital femoral epiphysis
[19,20]. Particularly, high risk of cervical vertebral abnormal-
ities (instability of C1–C2, os odontoideum, hypoplasia of
the dens, fusion of the cervical vertebrae) has been reported
[21-23], with possible stenosis at the craniovertebral junc-
tion, which may cause cervical myelopathy. Complex neuro-
radiological issues including corpus callosum dysgenesis
(17%) [24,25], Chiari type I malformation with or without
syringomyelia [25-28], Dandy Walker malformation andhydrocephalus [29,30], and tethered cord [27,31] have been
reported and are still under investigation. Cerebrovascular
abnormalities such as spontaneous dissection of the
supraaortic arteries [32] and cerebral infarction due to
dissecting aneurysm of the anterior cerebral artery
have also been reported [33]. However, any organ can
be affected in RSTS patients. Possible malformations,
medical problems, and complications include (Table 1):
– conductive and/or sensorineural deafness, recurrent
middle ear infections, recurrent respiratory
infections, immune deficiencies [34-36];
– nonspecific abnormalities of electroencephalography
(EEG) (57-66%) and seizures (25%) [37,38];
– cataract, unilateral or bilateral iris/retinal/optic
nerve coloboma (9-11%), glaucoma, lacrimal duct
obstructions (38-47%), refractive errors (41-56%),
and strabismus (60-71%) [39-41]. In addition, Jacobs
et al. described for the first time peripheral
avascularity with fluorescein angiography in 2012 [42];
– dental problems: talon cusps (73%), enamel
hypoplasia, and abnormal tooth number [43,44];
– congenital heart diseases: atrial septal defect,
ventricular septal defect, patent ductus arteriosus,
coarctation of the aorta, pulmonic stenosis, bicuspid
aortic valve, pseudotruncus, aortic stenosis,
dextrocardia, vascular rings, and conduction
disorders (24-38%) [45]. Occasional association of
hypoplastic left heart with RSTS has also been
reported [46];
– renal malformations (52%) and cryptorchidism
(78-100%) [47];
– endocrine disorders: congenital hypothyroidism
[48,49], thyroid hypoplasia, GH deficiency, and
pituitary hypoplasia [28];
– gastrointestinal disorders: gastroesophageal reflux,
constipation (40-74%), and megacolon/Hirschsprung
disease [47,50];
– obstructive sleep apnea, anesthetic and intubation
complications [51,52];
– skin problems including pilomatrixomas, ingrown
toenails, paronychia, and the tendency to form
keloids (24%) [53,54];
– cancers, particularly of neural and developmental
origins (neuroblastoma, medulloblastoma,
oligodendroglioma, meningeoma,
pheochromocytoma, rhabdomyosarcoma,
leiomyosarcoma, seminoma, odontoma, choristoma,
and pilomatrixomas [55-63]. Leukemia and
lymphoma have also been reported [55];
– hirsutism.
The neonatal period of individuals with RSTS is typ-
ically characterized by hypotonia and delayed psycho-
Figure 1 Typical facies of a RSTS patient, including arched eyebrows, slanted palpebral fissures, protruding beaked nose with
columella below alae nasi, arched palate, mild micrognathia, labial commissures facing upward, teeth anomalies, and an atypical smile
(“grimacing”) with nearly completely closed eyes.
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disability. For example, the intelligence quotient (IQ) score
of RSTS patients in neonatal period usually ranges from
25 to 79 (average: 36–51) [64,65]. In 2009, Galèra et al.
described three RSTS cardinal features, short attention
span, motor stereotypies, and poor coordination [66].
Both RSTS patients with classical RSTS and mild intellec-
tual disability [64,67] and RSTS patients with atypical
RSTS and mild intellectual disability have been reported
[68]. Therefore, in the mildest cases, an early diagnosis is
particularly difficult, and the main stages of development
must be strictly followed to rapidly initiate specific and
individualized stimulation. In addition, although RSTS
patients usually have friendly and sociable characteris-
tics, behavioral disorders, mood swings, and obsessive-
compulsive disorders can still be observed, particularly
in adulthood [64,65,69].Transition and healthcare in adulthood
Over 90% individuals with RSTS survive to adulthood
[70], and healthcare for these patients is particularly
complex, time-consuming, and often not standardized in
specific guidelines. The medical problems of most gen-
etic syndromes often change with ages and there is
limited knowledge about the management of adults
with genetic syndromes [71]. Adult individuals with
RSTS have been documented [13,59,68,72], but only a
few review studies on adults with RSTS are available
[40,57,69,73]. In these review studies, adult RSTS pa-
tients had relevant medical problems and most of them
had overweight or obesity. A number of behavioural
phenotypes such as anxiety, mood instability, and aggres-
sive behaviour can appear during adolescence. Caregivers
reported decreased abilities over time in 32% RSTS sub-
jects and some worsening behaviors in 37% RSTS patients,
Figure 2 Typical hands of a RSTS patient, including enlarged first finger and clinodactyly of the fifth finger.
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1992 [64]. Therefore, follow-up care is important to iden-
tify and treat the psychiatric problems that emerge with
age [65]. Finally, the prevalence of RSTS may be higher
than original estimation due to late diagnosis particularly
in the milder cases [74].
Diagnostic approaches
Individuals with suspected RSTS should be evaluated by
pediatric geneticists knowledgeable in dysmorphology. A
number of molecular techniques are widely used in gen-
etic analyses of RSTS. Among the assays, karyotype ana-
lysis may show rare cytogenetically visible abnormalities
(translocations, inversions, or deletions); although the
result is usually normal, this assessment should in any
case be performed to identify possible rearrangements.
FISH can identify microdeletions, with a detection rate
of 5-10% [38,75]. Deletion/duplication analysis testingidentifies exonic or whole-gene deletions/duplications not
detectable by sequence analysis of the coding and flanking
intronic regions of genomic DNA. Various methods may be
used (quantitative PCR, long-range PCR, multiplex ligation-
dependent probe amplification (MLPA), and chromosomal
microarray). Stef et al. detected deletions in 17 (20.5%)
of 83 patients using array-CGH and quantitative multi-
plex fluorescent-PCR [76]. Molecular analysis can also
identify mutations in CREBBP and EP300 genes. Patho-
genic variants of the CREBBP gene were identified in
50-70% of RSTS individuals [8,9,38,77], while mutations
in the EP300 gene have been reported in about 5-8% RSTS
patients by Roelfsema et al. [2005], Bartholdi et al. [2007],
Negri et al. [2014] [11,12,16].
Genotype-phenotype correlations
Little is known about genotype-phenotype correlations
of RSTS. A severe phenotype has been reported in RSTS
Table 1 The incidence of a number of typical features of
RSTS
Feature Incidence (%)
Typical facial features 100
Intellectual disability ~100
Cryptorchidism 78-100
Microcephaly 35-94
Broad thumbs/halluces 96
Speech delay 90
Recurrent respiratory infections 75
Delayed bone age 74
Constipation 40-74
Talon cusps 73
Gastroesophageal reflux 68
EEG abnormalities 57-66
Renal anomalies 52
Refractive defects, glaucoma, retinopathy >50
Congenital heart defects 24-38
Seizures 25
Keloids 24
Deafness 24
Growth retardation 21
Malignant tumors 3-10
Spinal cord tethering <5
Milani et al. Italian Journal of Pediatrics  (2015) 41:4 Page 5 of 9patients with large deletions [78], but other studies [76,79]
do not support this genotype-phenotype association.
However, an association between lower IQ and autistic
features with large deletions in RSTS patients is pos-
sible [38]. Therefore, Calì et al. recommended MLPA
that can identify these large deletions for screening RSTS
patients with lower IQ and autistic features [80]. Muta-
tions outside the histone acetyltransferase (HAT) domain
were associated with a mild phenotype [Spena et al., sub-
mitted]. In addition, somatic mosaicism may also be asso-
ciated with mild RSTS [9,81,82]. Less than 20 RSTSTable 2 Traditional medical guidelines for RSTS management
Diagnosis 6 M 1Y
Audiologic evaluation X X X
Ophtalmologic evaluation X X
Orthopedic evaluation X X X
Cardiologic evaluation* X
Pressure measurement
Renal US scan* X
Odonthoiatric evaluation X
Genetic counseling X
M=months, Y = years.
*Follow-up if necessary.patients with EP300 mutations have been identified and
characterized till now. EP300 mutations have been associ-
ated with preeclampsia in women carrying a pregnancy af-
fected by RSTS; skin involvement and a mild phenotype
in skeletal abnormalities and neuropsychiatric issues are
described [12-16,83].
Genetic counseling
Most RSTS cases are sporadic and only a few RSTS cases
affecting siblings have been reported to date [1,82,84-86].
Vertical transmission is extremely rare [75,86-89]. While
the recurrence risk of RSTS is generally low, proper gen-
etic counseling should be provided for prenatal diagnosis
of RSTS. Somatic mosacism, for example, was confirmed
in the clinically unaffected father of a boy with RSTS [82]
and in the mildly affected father of three females with
RSTS [89]. In addition, germline mosaicism was hypothe-
sized in two RSTS cases [17,82]. Based on these reports,
the recurrence risk of RSTS is approximately 0.5-1%.
Management
While significant advance in the knowledge of clinical
manifestations and natural history of RSTS has been
made, guidelines for the healthcare and follow-up care
of RSTS have not been well updated after the proposal
of Wiley et al. in 2003 (Table 2) [37]. Novel genetic and
epigenetic therapies may be promising approaches for
the treatment of RSTS [90,91], but there is an urgent
need to improve and personalize the standard follow up
protocol. On the basis of our knowledge and of the crit-
ical aspects that we discuss below, we drafted our pro-
posal for follow-up (Table 3).
Management should be adjusted in adolescent age, for
the known differences in some issues (ophthalmological
features, tendency to obesity and mood disorders in
particular).
Unknown and critical issues in RSTS
Substantial progress has been made in studies of the gen-
etic basis and medical issues of RSTS, which contributes18 M 2Y 30 M >3Y (yearly)
X X X X
X X X
X X X X
X
X X X X
Table 3 Our proposal for medical guidelines in patients with RSTS
Diagnosis 6 M 1Y 18 M 2Y 30 M >3Y (yearly) Adolescent age
Brain and medullary NMR* X X
Neuropsychiatric evaluation X X
Audiologic evaluation X X X X X X X X
Ophtalmologic evaluation X X X X X X
Orthopedic evaluation X X X X X X X X
Cardiologic evaluation* X X
Pressure measurement X X
Renal US scan* X X
Odonthoiatric evaluation X X X X X X
Endocrinological evaluation* X X X
Dermatologic evaluation* X X
Genetic counseling X X
M=months, Y = years.
*Follow-up if necessary.
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through molecular analyses. Given the complexity and
rarity of this syndrome, there are still numerous un-
answered questions about RSTS. Therefore, further inves-
tigations should be focused. on clinical diagnosis and
management as well as on genotype-phenotype correlation.
Based on our experience, abnormal growth patterns as
seen on standard growth charts should be highlighted in
the diagnostic criteria of RSTS. In addition, clinical diag-
nostic criteria and screening could be further classified
according to prenatal, childhood, and adolescent periods.
Particularly, the presence of normal growth in utero,
associated with other markers such as broad thumbs/
halluces and other malformations, is useful in differential
diagnosis of RSTS from other syndromes (i.e., Cornelia de
Lange syndrome). Pediatric geneticists should pay more
attention to widened distal phalanges: reviewing patients’
photos sent to molecular analyses we found in a great ma-
jority this sign, not reported in clinical charts. Enlarged
first finger is a feature largely known, but also common
in other syndromes such as acrocephalopolysyndactyly,
whereas distal phalanges conformation seems more
specific for RSTS. Moreover, talon cusps that are often
overlooked are also highly specific for RSTS. A multi-
center prevalence study of brain and spine abnormal-
ities is needed, in view of the several reports and of the
both diagnostic and prognostic meaning of these fea-
tures; a screening brain/medullary MRI could be useful
in addition to basic diagnostic work-up. Furthermore,
regarding endocrinological features, more informations
were recently added, regarding in particular thyroid
shape and function, and we are personally aware of
other two cases with mild hypothyiroidism and small
thyroid. In addition to intellectual disability, some behavioralchanges are known for RSTS patients, but no signifi-
cant evidence supports the diagnostic values of these
neuropsychiatric features in RSTS diagnosis. Therefore,
no neuropsychiatric features are strong enough to be in-
cluded in the diagnostic criteria of RSTS although some
features may be more suggestive of EP300 mutations. In
these cases, ID is mild or absent, and behavioral disturb-
ance (i.e. anxiety) predominates. Other features suggestive
of EP300 mutations include pre-eclampsia [92] and less
significant abnormalities in the firs digit, giving the cue for
drawing up differential criteria for EP300, and for a more
precise and individualized laboratory flow-chart. To the
best of our knowledge, this is the only possible change in
the order of molecular investigations, as other genotype-
phenotype correlations are only tentative. Numerous non-
specific complications may occur during the follow-up
care of RSTS; therefore, it is difficult to establish a general
and efficient follow-up protocol. In addition, no robust
genotype-phenotype correlations have been identified. In
general, orthopaedic follow-up, dietary monitoring in ado-
lescence and neuropsychiatric periods, and ophthalmo-
logic evaluations in adults should be focused. A less strict
follow-up protocol may be only appropriate for RSTS
patients with EP300 mutations [16], with focus on skin
problems (pilomatrixomas and nevi) that are likely
more frequent than in patients with CREBBP muta-
tions. Regarding genetic counselling, salivary brush
and genetic tests are important for the evaluation of
recurrence risk in parents with germinal and somatic
mosaicism.
A discussion about critical aspects of progresses in un-
derstanding of RSTS etiopathogenesis is out of the scope
of this review, but different mouse models have been
made with interesting results [90].
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RSTS is an extremely rare condition for which some
clinical aspects have been clearly identified, but a lot of
studies are ongoing and needed. Multicenter studies are
needed to expand our knowledge on the clinical pheno-
type, identify specific genotype-phenotype correlations,
evaluate the presence of somatic mosaicisms to better
define mild phenotypes, and identify new candidate
genes. The ultimate goal of these studies is to extend
our current knowledge concerning this syndrome and to
define new international guidelines for diagnosis, care
and treatment of patients with RSTS.Summary
RSTS is an extremely rare multiple congenital anomaly/
intellectual disability syndrome, with an estimated preva-
lence of one case per 125,000 live births. No precise
diagnostic criteria have been defined, although the dis-
tinctive features include typical facial features, microceph-
aly, broad thumbs and first toes, intellectual disability and
postnatal growth retardation. RSTS is mainly character-
ized by poor growth in height and weight, microcephaly,
dysmorphic facial features, broad thumbs and big toe. Sev-
eral organs and systems may be affected, but none of other
signs or symptoms can be considered pathognomonic.
More than 90% of individuals with disabilities survive into
adulthood, and health care for these patients is particularly
complex, time-consuming, often not standardized in spe-
cific guidelines. The gene most frequently involved is
cyclic-AMP-regulated enhancer binding protein (CREBBP);
alterations in the E1A-binding protein p300 (EP300) have
also been detected, but many cases have only been clinic-
ally diagnosed. Future multicenter studies are necessary to
expand our knowledge on the clinical phenotype, iden-
tify specific genotype-phenotype correlations, evaluate
the presence of somatic mosaicisms to better define
mild phenotypes, and identify new candidate genes.
The ultimate goal of these studies is to extend our
current knowledge concerning this syndrome and to
define new international guidelines for diagnosis, care
and treatment of patients with RSTS.Ethical approval
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